FDMT 6.31 (+9.17%)
US35104E1001BiotechnologyBiotechnology

4D Molecular Therapeutics (FDMT) Stock Highlights

6.31 | +9.17%
2024-12-21 05:37:16
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

Statistics

Range Today
5.74 6.37
Volume Today 4.76M
Range 1 Year
5.58 36.25
Volume 1 Year 221.85M
Range 3 Year
5.32 36.25
Volume 3 Year 402.8M
Range 10 Year
5.32 55.11
Volume 10 Year 455.92M

Highlights

Market Capitalization 421.99M (small)
Floating Shares 26.4M
Current Price 6.31
Price To Earnings -3.78
Price To Revenue -5.26
Price To Book 0.72
Earnings Per Share -2.2
Payout Ratio 0%

Performance

Latest +9.17%
1 Month -27.89%
3 Months -53.4%
6 Months -72.21%
1 Year -68.43%
3 Years -67.67%
5 Years -84.22%
10 Years -84.22%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.